Gene · 10683
Papers2,335
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,335
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab. | bioRxiv | 2026 | 42818314 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges. | Curr Issues Mol Biol | 2026 | 42793224 | PubTator, text mining | PubMed |
| Recent advances and future challenges of bispecific antibodies in lung cancer. | Crit Rev Oncol Hematol | 2026 | 42778079 | PubTator, text mining | PubMed |
| Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection. | Front Immunol | 2026 | 42761714 | PubTator, text mining | PubMed |
| γδ T cells modulate anti-tumor immunity in small cell lung cancer. | Cancer Cell | 2026 | 42759517 | PubTator, text mining | PubMed |
| Navigating tarlatamab and bispecific T-cell engager therapy in small cell lung cancer: A narrative review. | Cancer Treat Res Commun | 2026 | 42753581 | PubTator, text mining | PubMed |
| What are the Unmet Needs in Managing Digestive Neuroendocrine Carcinomas? | Curr Oncol Rep | 2026 | 42747588 | PubTator, text mining | PubMed |
| Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles. | Histopathology | 2026 | 42747234 | PubTator, text mining | PubMed |
| T-Cell Engagers in Lung Cancer: A Comprehensive Literature Review from Tarlatamab Approval to Next-Generation Strategies. | Cancers (Basel) | 2026 | 42738247 | PubTator, text mining | PubMed |
| Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report. | JTO Clin Res Rep | 2026 | 42733924 | PubTator, text mining | PubMed |
| SCLC TumorMiner: A genomics platform for small cell lung cancer precision oncology. | iScience | 2026 | 42733745 | PubTator, text mining | PubMed |
| Advances in understanding the tumor microenvironment of neuroendocrine prostate cancer. | Front Oncol | 2026 | 42729787 | PubTator, text mining | PubMed |
| Advanced and underlying therapeutic strategies in transformed small cell lung cancer. | Front Med (Lausanne) | 2026 | 42724635 | PubTator, text mining | PubMed |
| T-cell engagers in small cell lung cancer. | Cancer | 2026 | 42723523 | PubTator, text mining | PubMed |
| Cell Surface Expression and PET Imaging Establish DLL3 as a Clinically Actionable Target in Neuroblastoma. | J Nucl Med | 2026 | 42722443 | PubTator, text mining | PubMed |
| Guillain-Barré Syndrome Following the Administration of Tarlatamab in Extensive-stage Small Cell Lung Cancer: A Case Report with Pathological Confirmation. | Intern Med | 2026 | 42716745 | PubTator, text mining | PubMed |
| Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors. | J Hematol Oncol | 2026 | 42711696 | PubTator, text mining | PubMed |
| [Expert Consensus on Immunotherapy for Extensive-stage Small Cell Lung Cancer Based on Molecular Subtyping]. | Zhongguo Fei Ai Za Zhi | 2026 | 42705850 | PubTator, text mining | PubMed |
| EGFR-Mutant Non-Small Cell Lung Cancer With Small Cell Transformation: Clinicopathological Features, Treatment Landscape, and Biomarker Profiles. | JTO Clin Res Rep | 2026 | 42699526 | PubTator, text mining | PubMed |
| A review on toxicities of T-cell engager-based therapies in solid tumors. | Ther Adv Med Oncol | 2026 | 42676742 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10683/papers